TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cognitive Enhancer May Facilitate Behavioral Exposure Therapy for Veterans With PTSD
Brief Summary: This study will determine whether a combination of virtual reality exposure therapy and D-cycloserine will reduce post-traumatic stress disorder symptoms in Iraq war veterans.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): N/A
B: Arm Label: D-cycloserine plus exposure therapy; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine, Behavioral: Exposure therapy | Arm Label: Placebo plus exposure therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Exposure therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus exposure therapy | Intervention Type: BEHAVIORAL; Name: Exposure therapy; Assigned to Arm(s): D-cycloserine plus exposure therapy, Placebo plus exposure therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus exposure therapy
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: D-Cycloserine, Behavioral: Virtual Reality Exposure Therapy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alprazolam, Behavioral: Virtual Reality Exposure Therapy | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Virtual Reality Exposure Therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Alprazolam; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Virtual Reality Exposure Therapy; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C
D: Arm Label: Cognitive Behavioral Group Therapy + D-Cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: D-Cycloserine | Arm Label: Cognitive Behavioral Group Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy (CBGT); Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine, Cognitive Behavioral Group Therapy + Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cognitive Behavioral Group Therapy + Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label, Long-term Extension Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis Who Participated in Protocol 16.0037
Brief Summary: The purpose of this study was to evaluate extended safety and efficacy of etanercept in adults with Ankylosing Spondylitis.


Options:
A: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
B: Arm Label: All subjects; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): All subjects
C: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Strengthening in Native Communities Project
Brief Summary: The goals of this study are to evaluate the effects of an in-home parenting education program, called Family Spirit, on parenting knowledge and skills and decreasing alcohol and substance use compared to a breast-feeding education. In addition, we will assess aspects of mother/child interaction.


Options:
A: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care
B: Arm Label: Group Education; Type: EXPERIMENTAL; Interventions: Other: Group Education | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Group Education; Assigned to Arm(s): Group Education
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ACOG education pamphlet on preeclampsia | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Preeclampsia education tool | Intervention Type: BEHAVIORAL; Name: ACOG education pamphlet on preeclampsia; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Preeclampsia education tool; Assigned to Arm(s): 3
D: Intervention Type: BEHAVIORAL; Name: Family Spirit curriculum; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Strengthening in Native Communities Project
Brief Summary: The goals of this study are to evaluate the effects of an in-home parenting education program, called Family Spirit, on parenting knowledge and skills and decreasing alcohol and substance use compared to a breast-feeding education. In addition, we will assess aspects of mother/child interaction.


Options:
A: Arm Label: Family Spirit Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Family Spirit Intervention | Arm Label: Optimized Standard Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Family Spirit Intervention; Assigned to Arm(s): Family Spirit Intervention
B: Intervention Type: BEHAVIORAL; Name: Family Spirit curriculum; Assigned to Arm(s): N/A
C: Arm Label: intervention 1; Type: EXPERIMENTAL; Interventions: Behavioral: classroom curriculum, Behavioral: In-service training for Head Start teachers/aides, Behavioral: Training for Head Start food service, Behavioral: Family intervention component, Behavioral: Food source, Behavioral: Health care providers, Behavioral: CHILE Head Start Intervention | Arm Label: control 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: classroom curriculum; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: In-service training for Head Start teachers/aides; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Training for Head Start food service; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Family intervention component; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Food source; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Health care providers; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: CHILE Head Start Intervention; Assigned to Arm(s): intervention 1
D: Arm Label: COHS administered fluoride varnish and oral health education; Type: EXPERIMENTAL; Interventions: Device: Fluoride varnish, Behavioral: Oral health education | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Dental services delivered by the Indian Health Service. | Intervention Type: DEVICE; Name: Fluoride varnish; Assigned to Arm(s): COHS administered fluoride varnish and oral health education | Intervention Type: BEHAVIORAL; Name: Oral health education; Assigned to Arm(s): COHS administered fluoride varnish and oral health education | Intervention Type: OTHER; Name: Dental services delivered by the Indian Health Service.; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observational, Cross-over Study of the Positive Distending Pressure Generated by Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure
Brief Summary: The specific aims of this study are to evaluate the amount of high flow nasal cannula (HFNC) gas flow required to generate an equivalent positive distending pressure as that provided by nasal continuous positive airway pressure (NCPAP) of 6 cm H2O, assess the relationships between positive distending pressure, gas flow, oxygen requirement, and patient weight, and lastly, develop an appropriate protocol to be used in the NICU for transitioning patients from NCPAP to an equivalent amount of HFNC.


Options:
A: Arm Label: HFNC; Type: EXPERIMENTAL; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Intervention Type: DEVICE; Name: Respiratory support HFNC; Assigned to Arm(s): HFNC, nCPAP | Intervention Type: DEVICE; Name: Respiratory support NCPAP; Assigned to Arm(s): HFNC, nCPAP
B: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support
C: Arm Label: CPAP group; Type: EXPERIMENTAL; Interventions: Device: CPAP | Arm Label: Nasal Cannula Group; Type: EXPERIMENTAL; Interventions: Device: Nasal Cannula | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP group | Intervention Type: DEVICE; Name: Nasal Cannula; Assigned to Arm(s): Nasal Cannula Group
D: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observational, Cross-over Study of the Positive Distending Pressure Generated by Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure
Brief Summary: The specific aims of this study are to evaluate the amount of high flow nasal cannula (HFNC) gas flow required to generate an equivalent positive distending pressure as that provided by nasal continuous positive airway pressure (NCPAP) of 6 cm H2O, assess the relationships between positive distending pressure, gas flow, oxygen requirement, and patient weight, and lastly, develop an appropriate protocol to be used in the NICU for transitioning patients from NCPAP to an equivalent amount of HFNC.


Options:
A: Arm Label: HHFNC; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Intervention Type: OTHER; Name: Nasal CPAP; Assigned to Arm(s): HHFNC, nCPAP | Intervention Type: OTHER; Name: Humidified High Flow Nasal Cannula (HHFNC); Assigned to Arm(s): HHFNC, nCPAP
B: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A
C: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group
D: Arm Label: HFNC; Type: EXPERIMENTAL; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Intervention Type: DEVICE; Name: Respiratory support HFNC; Assigned to Arm(s): HFNC, nCPAP | Intervention Type: DEVICE; Name: Respiratory support NCPAP; Assigned to Arm(s): HFNC, nCPAP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome
Brief Summary: Erythropoietin (EPO) treatment in patients with the severe cardiorenal syndrome increases cardiac performance and decreases progression of renal failure by dampening the main driving forces of the cardiorenal syndrome in part via non-erythropoietic pathways.

I. Does EPO administration to patients with the severe cardiorenal syndrome increase cardiac performance and decrease progression of renal disease?

II. Does EPO treatment affect the main driving forces of the cardiorenal connection, that is, dampen the activated renin-angiotensin system (RAS), attenuate increased reactive oxygen species (ROS), normalize increased sympathetic activity, and decrease inflammation?

III. Does EPO treatment positively affect the cell function of patients with the cardiorenal syndrome:

1. are gene expression signatures of leukocytes positively influenced by EPO treatment,
2. does EPO shift the Jak/STAT pathway to a less pro-inflammatory profile in monocytes, and
3. are function and number of endothelial progenitor cells (EPCs) affected by treatment with EPO in the cardiorenal syndrome?

IV. Can the direct actions of EPO be differentiated from the effects on hemoglobin levels?


Options:
A: Intervention Type: DRUG; Name: GerEPO; Assigned to Arm(s): N/A
B: Arm Label: EPO rise; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: EPO stable; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin administration; Assigned to Arm(s): EPO rise, EPO stable
C: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
D: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome
Brief Summary: Erythropoietin (EPO) treatment in patients with the severe cardiorenal syndrome increases cardiac performance and decreases progression of renal failure by dampening the main driving forces of the cardiorenal syndrome in part via non-erythropoietic pathways.

I. Does EPO administration to patients with the severe cardiorenal syndrome increase cardiac performance and decrease progression of renal disease?

II. Does EPO treatment affect the main driving forces of the cardiorenal connection, that is, dampen the activated renin-angiotensin system (RAS), attenuate increased reactive oxygen species (ROS), normalize increased sympathetic activity, and decrease inflammation?

III. Does EPO treatment positively affect the cell function of patients with the cardiorenal syndrome:

1. are gene expression signatures of leukocytes positively influenced by EPO treatment,
2. does EPO shift the Jak/STAT pathway to a less pro-inflammatory profile in monocytes, and
3. are function and number of endothelial progenitor cells (EPCs) affected by treatment with EPO in the cardiorenal syndrome?

IV. Can the direct actions of EPO be differentiated from the effects on hemoglobin levels?


Options:
A: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
C: Arm Label: EPO rise; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: EPO stable; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin administration; Assigned to Arm(s): EPO rise, EPO stable
D: Arm Label: CKD-11101(Darbepoetin alfa); Type: EXPERIMENTAL; Interventions: Biological: CKD-11101(Darbepoetin alfa) | Arm Label: NESP(Darbepoetin alfa); Type: ACTIVE_COMPARATOR; Interventions: Biological: NESP(Darbepoetin alfa) | Intervention Type: BIOLOGICAL; Name: CKD-11101(Darbepoetin alfa); Assigned to Arm(s): CKD-11101(Darbepoetin alfa) | Intervention Type: BIOLOGICAL; Name: NESP(Darbepoetin alfa); Assigned to Arm(s): NESP(Darbepoetin alfa)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Influence of Increasing Awareness of Cardiac Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery to Cardiac Rehabilitation (CR) on Actual Participation Rates and; Patients' Related Barriers to CR Programs Participation
Brief Summary: The main aim of the study is to determine the effectiveness of an educational intervention designed to increase attendance of coronary artery bypass grafting (CABG) patients at Cardiac Rehabilitation Programs (CRPs) on actual CRP participation rate and; examine patient-related factors (demographic, health, psychosocial, awareness) influencing patients' attendance at CRPs. We hypothesized that the proportion of CABG patients participating in CRPs will increase significantly to 20-30% following the educational intervention employed.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Web Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web intervention | Arm Label: Nurse Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: nurse intervention | Intervention Type: BEHAVIORAL; Name: web intervention; Assigned to Arm(s): Web Intervention | Intervention Type: BEHAVIORAL; Name: nurse intervention; Assigned to Arm(s): Nurse Intervention
B: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management
C: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: educational program+telephone follow up; Type: EXPERIMENTAL; Interventions: Behavioral: educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: educational program+telephone follow up; Assigned to Arm(s): educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): usual care
D: Arm Label: Explanation on cardiac rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Increasing awareness to cardiac rehabilitation programs | Arm Label: Usual care with no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing awareness to cardiac rehabilitation programs; Assigned to Arm(s): Explanation on cardiac rehabilitation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
B: Arm Label: The STOP intervention; Type: EXPERIMENTAL; Interventions: Other: The STOP intervention | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: The STOP intervention; Assigned to Arm(s): The STOP intervention | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
D: Arm Label: tobacco cigarette; Type: ACTIVE_COMPARATOR; Interventions: Other: Tobacco cigarette | Arm Label: e.cigarettes + 16mg nicotine & flavor; Type: ACTIVE_COMPARATOR; Interventions: Device: electronic cigarette + 16mg nicotine & flavor | Arm Label: e.cigarettes + 0mg nicotine & flavour; Type: ACTIVE_COMPARATOR; Interventions: Other: electronic cigarette + 0mg nicotine & flavor | Intervention Type: DEVICE; Name: electronic cigarette + 16mg nicotine & flavor; Assigned to Arm(s): e.cigarettes + 16mg nicotine & flavor | Intervention Type: OTHER; Name: electronic cigarette + 0mg nicotine & flavor; Assigned to Arm(s): e.cigarettes + 0mg nicotine & flavour | Intervention Type: OTHER; Name: Tobacco cigarette; Assigned to Arm(s): tobacco cigarette

Answer: A